Stocktoria
IMPACT BIOMEDICAL INC. IBO
NYSE American · XASE · stock · Pharmaceutical Preparations · website · IPO 2024-09-16
IMPACT BIOMEDICAL INC. financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $32,000 | — | — | $50,000 |
| R&D expense | $340,000 | $278,000 | $1.7M | $1.2M |
| SG&A expense | $873,000 | $718,000 | $315,000 | $325,000 |
| Operating income | -$4.3M | -$28.8M | -$4.0M | -$3.4M |
| Interest expense | $793,000 | $1.1M | $444,000 | $462,000 |
| Income tax | -$2.6M | $33,000 | — | -$621,000 |
| Net income | -$11.8M | -$24.7M | -$4.3M | -$7.3M |
| EPS (diluted) | $-0.38 | $-2.30 | $-0.07 | $-0.10 |
| Operating cash flow | -$1.9M | -$2.9M | -$2.9M | -$2.2M |
| Cash & equivalents | $3,000 | $2.0M | $1,000 | $2,000 |
| Inventory | $63,000 | — | — | — |
| Total assets | $17.4M | $20.3M | $44.6M | $46.5M |
| Total liabilities | $1.9M | $13.1M | $16.4M | $13.8M |
| Shareholders' equity | $15.6M | $7.2M | $28.3M | $32.7M |
Source: SEC EDGAR filings · CIK 0001834105 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.